Cargando…
Cognitive and Adaptive Effects of Early Growth Hormone Treatment in Prader–Willi Syndrome Patients: A Cohort Study
Background: Prader–Willi Syndrome (PWS) is a genetically based neurodevelopmental disease characterized by obesity, hyperphagia, and mild to moderate intellectual disability. Treatment with growth hormone (GH) could provide cognitive benefits. The objective of the present study was to compare the co...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8955812/ https://www.ncbi.nlm.nih.gov/pubmed/35329918 http://dx.doi.org/10.3390/jcm11061592 |
_version_ | 1784676428586942464 |
---|---|
author | Ayet-Roger, Aitana Joga-Elvira, Lorena Caixàs, Assumpta Corripio, Raquel |
author_facet | Ayet-Roger, Aitana Joga-Elvira, Lorena Caixàs, Assumpta Corripio, Raquel |
author_sort | Ayet-Roger, Aitana |
collection | PubMed |
description | Background: Prader–Willi Syndrome (PWS) is a genetically based neurodevelopmental disease characterized by obesity, hyperphagia, and mild to moderate intellectual disability. Treatment with growth hormone (GH) could provide cognitive benefits. The objective of the present study was to compare the cognitive and adaptive performance of 31 patients with genetically confirmed PWS grouped in two cohorts, one treated with GH before 2 years old (Group 1) and the other receiving the treatment later (Group 2). Method: We compared two variables necessary to diagnose intellectual disability: intellectual performance, using the Weschler scales, and adaptive behavior, using the DABS scale. The scores were analyzed by means of non-parametric statistical tests. Results: Group 1 (n = 10) obtained higher and statistically significant scores in Total Intelligence Quotient (TIQ), General Ability Index (GAI), and General Adaptive Behavior (GAB), implying better cognitive and adaptive performance compared to Group 2. Conclusions: Treatment with GH should be administered in the early stage of development (before 2 years old) to obtain greater benefits at the cognitive and adaptive levels. |
format | Online Article Text |
id | pubmed-8955812 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-89558122022-03-26 Cognitive and Adaptive Effects of Early Growth Hormone Treatment in Prader–Willi Syndrome Patients: A Cohort Study Ayet-Roger, Aitana Joga-Elvira, Lorena Caixàs, Assumpta Corripio, Raquel J Clin Med Article Background: Prader–Willi Syndrome (PWS) is a genetically based neurodevelopmental disease characterized by obesity, hyperphagia, and mild to moderate intellectual disability. Treatment with growth hormone (GH) could provide cognitive benefits. The objective of the present study was to compare the cognitive and adaptive performance of 31 patients with genetically confirmed PWS grouped in two cohorts, one treated with GH before 2 years old (Group 1) and the other receiving the treatment later (Group 2). Method: We compared two variables necessary to diagnose intellectual disability: intellectual performance, using the Weschler scales, and adaptive behavior, using the DABS scale. The scores were analyzed by means of non-parametric statistical tests. Results: Group 1 (n = 10) obtained higher and statistically significant scores in Total Intelligence Quotient (TIQ), General Ability Index (GAI), and General Adaptive Behavior (GAB), implying better cognitive and adaptive performance compared to Group 2. Conclusions: Treatment with GH should be administered in the early stage of development (before 2 years old) to obtain greater benefits at the cognitive and adaptive levels. MDPI 2022-03-14 /pmc/articles/PMC8955812/ /pubmed/35329918 http://dx.doi.org/10.3390/jcm11061592 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Ayet-Roger, Aitana Joga-Elvira, Lorena Caixàs, Assumpta Corripio, Raquel Cognitive and Adaptive Effects of Early Growth Hormone Treatment in Prader–Willi Syndrome Patients: A Cohort Study |
title | Cognitive and Adaptive Effects of Early Growth Hormone Treatment in Prader–Willi Syndrome Patients: A Cohort Study |
title_full | Cognitive and Adaptive Effects of Early Growth Hormone Treatment in Prader–Willi Syndrome Patients: A Cohort Study |
title_fullStr | Cognitive and Adaptive Effects of Early Growth Hormone Treatment in Prader–Willi Syndrome Patients: A Cohort Study |
title_full_unstemmed | Cognitive and Adaptive Effects of Early Growth Hormone Treatment in Prader–Willi Syndrome Patients: A Cohort Study |
title_short | Cognitive and Adaptive Effects of Early Growth Hormone Treatment in Prader–Willi Syndrome Patients: A Cohort Study |
title_sort | cognitive and adaptive effects of early growth hormone treatment in prader–willi syndrome patients: a cohort study |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8955812/ https://www.ncbi.nlm.nih.gov/pubmed/35329918 http://dx.doi.org/10.3390/jcm11061592 |
work_keys_str_mv | AT ayetrogeraitana cognitiveandadaptiveeffectsofearlygrowthhormonetreatmentinpraderwillisyndromepatientsacohortstudy AT jogaelviralorena cognitiveandadaptiveeffectsofearlygrowthhormonetreatmentinpraderwillisyndromepatientsacohortstudy AT caixasassumpta cognitiveandadaptiveeffectsofearlygrowthhormonetreatmentinpraderwillisyndromepatientsacohortstudy AT corripioraquel cognitiveandadaptiveeffectsofearlygrowthhormonetreatmentinpraderwillisyndromepatientsacohortstudy |